Summit Therapeutics
SMMT
13 hedge funds and large institutions have $24.8M invested in Summit Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.
18% more funds holding
Funds holding: 11 → 13 (+2)
13% more capital invested
Capital invested by funds: $21.9M → $24.8M (+$2.85M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JCM
Jacobi Capital Management
Pittston,
Pennsylvania
|
+$3.61K |
| 2 |
Axa
Paris,
France
|
+$2.52K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.52K |
| 4 |
Morgan Stanley
New York
|
+$1.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$53.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.42K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.98K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.44K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $8.43M | – | – | – |
|
2
Point72 Asset Management
Stamford,
Connecticut
| $8.39M | – | – | – |
|
|
3
Axa
Paris,
France
| $3.47M | +$2.52K | +349 | +0.1% |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $1.81M | – | – | – |
|
5
First Eagle Investment Management
New York
| $1.61M | – | – | – |
|
|
GPCM
6
Granite Point Capital Management
Boston,
Massachusetts
| $954K | -$53.5K | -7,415 | -7% |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $54K | +$2.52K | +349 | +6% |
|
|
8
UBS Group
Zurich,
Switzerland
| $12K | -$2.42K | -335 | -20% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $11K | -$1.98K | -274 | -18% |
|
|
10
Wells Fargo
San Francisco,
California
| $11K | -$1.44K | -200 | -14% |
|
|
JCM
11
Jacobi Capital Management
Pittston,
Pennsylvania
| $7K | +$3.61K | +500 | New |
|
|
12
Morgan Stanley
New York
| $2K | +$1.8K | +250 | New |
|
|
LTFS
13
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
SMMT Hedge Fund Activity: Q3 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2016, worth a combined $24.8M — up 13% from $21.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SMMT positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Jacobi Capital Management, opening a new position worth an estimated $3.61K. The largest seller was Granite Point Capital Management, cutting an estimated $53.5K.
- 13 institutional investors held Summit Therapeutics (SMMT) as of Q3 2016, up from 11 in Q2 2016.
- Funds reported $24.8M of Summit Therapeutics stock for Q3 2016, up 13% quarter-over-quarter.
- 2 funds opened new Summit Therapeutics positions in Q3 2016 and 0 closed out, a net change of +2 holders.
- The largest Summit Therapeutics buyer in Q3 2016 was Jacobi Capital Management, an estimated $3.61K added.
- The largest Summit Therapeutics seller in Q3 2016 was Granite Point Capital Management, an estimated $53.5K sold.
Based on aggregated 13F filings for Q3 2016.